(RTTNews) - Replimune Group, Inc. (REPL), a clinical-stage biotechnology company, on Wednesday announced the first patient has been dosed in two clinical trials evaluating RP2, its oncolytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results